Shire's Acquisition by Takeda

Takeda, a global pharmaceutical company, acquired Shire, a biopharmaceutical firm specializing in rare diseases and specialty medicines, in 2019 for approximately $62 billion. This strategic move expanded Takeda’s portfolio of specialty treatments, strengthened its international presence, and boosted its research capabilities. The acquisition allowed Takeda to diversify its offerings beyond its core areas, gaining access to Shire’s advanced pipeline and expertise in rare disorders. Overall, it was a significant effort by Takeda to become a leading global player in innovative medicines, broadening its reach in specialized healthcare markets.